TOP TEN perturbations for Q8NHX9 (Homo sapiens)

Organism: Homo sapiens
Gene: Q8NHX9
Selected probe(set): 229250_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of Q8NHX9 (229250_at) across 5610 perturbations tested by GENEVESTIGATOR:

CAR T cell study 4 (PSCA-8t28BBZ; post-infusion) / CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)

Relative Expression (log2-ratio):2.6573143
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-8t28BBZ; post-infusion)
CD8+ T cells transduced with PSCA-8t28BBZ (third generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-8t28BBZ. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-8t28BBZ; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-8t28BBZ (third generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-8t28BBZ. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)

Relative Expression (log2-ratio):2.480195
Number of Samples:3 / 3
Experimental CAR T cell study 4 (PSCA-28t28Z; post-infusion)
CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples).
Control CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples).

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):2.376668
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

hepatitis C virus study 1 (late) / mock infected HuH-7 cell sample

Relative Expression (log2-ratio):-2.32016
Number of Samples:3 / 3
Experimental hepatitis C virus study 1 (late)
HuH-7 hepatocellular carcinoma cells infected with the genotype 2a hepatitis C virus clone JFH-1. Cells were infected at a multiplicity of infection (MOI) of 3 and RNA was extracted at 48 hours post-infection.
Control mock infected HuH-7 cell sample
HuH-7 hepatocellular carcinoma cells mock infected with concentrated conditioned growth medium. RNA was extracted at 48 hours post-infection.

B-CLL study 11 (rolipram) / B-CLL study 11 (DMSO)

Relative Expression (log2-ratio):1.9353123
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.

Langerhans cell histiocytosis study 1 / normal myeloid dendritic cell sample

Relative Expression (log2-ratio):-1.8235054
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal myeloid dendritic cell sample
Normal myeloid dendritic cells were isolated from peripheral blood of healthy adult donors. Myeloid dendritic cells were defined as HLA-DR+ / CD11c + / BDCA1+ / BDCA3- population.

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-1.813179
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

leprosy study 1 (LL) / leprosy study 1 (BTL)

Relative Expression (log2-ratio):1.7535706
Number of Samples:6 / 10
Experimental leprosy study 1 (LL)
Lesional skin biopsy samples from patients with lepromatous leprosy (LL).
Control leprosy study 1 (BTL)
Lesional skin biopsy samples from patients with borderline tuberculoid leprosy (BTL)

interferon-alpha-kinoid study 1 (240ug; 168d) / untreated whole blood sample

Relative Expression (log2-ratio):1.7360096
Number of Samples:2 / 43
Experimental interferon-alpha-kinoid study 1 (240ug; 168d)
Whole blood samples of patients with systemic lupus erythematosus after treatment with interferon-alpha-kinoid (INF-K; inactivated IFNa coupled keyhole limpet hemocyanin as carrier). Patients had 3 doses of 240ug INK-K at day 0, 7 and 58. Sample was taken 168 days after the first application of TNF-K. ATC code:---
Control untreated whole blood sample
Whole blood samples from healthy volunteers.

pancreatic cancer study 3 (ipmn) / normal pancreas tissue

Relative Expression (log2-ratio):1.6766376
Number of Samples:3 / 6
Experimental pancreatic cancer study 3 (ipmn)
Intraductal papillary mucinous neoplasm from patients with pancreatic cancer.
Control normal pancreas tissue
Normal human pancreatic tissue.